Adjuvant Chemotherapy in Node-negative Breast Cancer: Chemo N0
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Prognostic impact of uPA/PAI-1: Number of patients disease-free in low vs. high risk groups according to uPA/PAI-1
Interim analyses planned at 4.5, 6.5, and 8.5 years after first patient in. Final analysis scheduled at 10.5 years after last patient in.
DFS at 3, 5, and 10 years (depending on analysis time point)
Fritz Jaenicke, MD
Germany: German Research Foundation